We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dalfampridine in hereditary spastic paraplegia: a prospective, open study.
- Authors
Béreau, Matthieu; Anheim, Mathieu; Chanson, Jean-Baptiste; Tio, Grégory; Echaniz-Laguna, Andoni; Depienne, Christel; Collongues, Nicolas; Sèze, Jérôme
- Abstract
Our aim was to support the use of dalfampridine as a treatment for patients affected with hereditary spastic paraplegia (HSP). We performed a prospective, uncontrolled, proof of concept, open trial. We included 12 HSP patients defining the total group (TG) who received dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement. The Timed-25-Foot Walk Test, the Spastic Paraplegia Rating Scale (SPRS), and the 12-item Multiple Sclerosis Walking Scale (MSWS-12) were performed before and after treatment. Safety assessment was based on adverse events occurrence. A significant improvement in SPRS ( p = 0.0195) and MSWS-12 ( p = 0.0429) was noted after treatment in the TG. No serious adverse events were noted. This interventional study provides encouraging results supporting the use of dalfampridine in HSP.
- Subjects
PARAPLEGIA; LEG diseases; GENETIC disorder treatment; GAIT disorder treatment; HEAT shock proteins; THERAPEUTICS
- Publication
Journal of Neurology, 2015, Vol 262, Issue 5, p1285
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-015-7707-6